International Journal of Inflammation, Cancer and Integrative Therapy
Open Access

Bladder cancer is one of the most common malignancies worldwide, with significant morbidity and mortality. The management of bladder cancer involves a combination of surgery, chemotherapy, radiotherapy, and immunotherapy. The identification and application of biomarkers have become essential in the diagnosis, prognosis, and treatment of bladder cancer. This article delves into the current landscape of bladder cancer biomarkers, their clinical significance and the future prospects in this rapidly evolving field [1].

Understanding bladder cancer

Bladder cancer primarily originates from the urothelial cells lining the bladder. It can be categorized into non-muscle-invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC). NMIBC accounts for approximately 70% of all bladder cancer cases and is generally associated with a better prognosis compared to MIBC, which has a higher tendency to metastasize and requires more aggressive treatment [2].

Current biomarkers in bladder cancer

Urinary biomarkers

NMP22 (Nuclear matrix protein 22): NMP22 is a protein associated with the nuclear matrix of cells, and its elevated levels in urine are indicative of bladder cancer. NMP22 is used as a non-invasive diagnostic marker, particularly for detecting recurrence in NMIBC.

UBC (Urinary bladder cancer antigen): UBC is another protein found in the urine of bladder cancer patients. It is used to aid in the diagnosis and monitoring of bladder cancer, especially in combination with other tests [3].

Survivin: Survivin is an inhibitor of apoptosis protein that is often overexpressed in bladder cancer cells. Detection of survivin in urine can help in diagnosing bladder cancer and predicting disease recurrence.

Tissue biomarkers

FGFR3 (Fibroblast growth factor receptor 3): Mutations in the FGFR3 gene are common in NMIBC. FGFR3 mutations are associated with a favorable prognosis and can guide the use of targeted therapies.

TP53: Mutations in the TP53 gene are frequently observed in MIBC and are associated with a poor prognosis. TP53 status can help in risk stratification and treatment planning.

Ki-67: Ki-67 is a marker of cellular proliferation. High levels of Ki-67 expression are indicative of aggressive tumor behavior and poor prognosis.

Blood biomarkers

CEA (Carcinoembryonic antigen): Elevated levels of CEA in the blood can be found in bladder cancer patients. While not specific to bladder cancer, CEA can be used in conjunction with other markers for monitoring disease progression and treatment response [4].

CA 19-9 (Carbohydrate antigen 19-9): Similar to CEA, CA 19-9 is not specific to bladder cancer but can be elevated in some patients. It is used primarily for monitoring purposes.

Molecular biomarkers

PD-L1 (Programmed death-ligand 1): PD-L1 expression on tumor cells and immune cells is used to predict response to immune checkpoint inhibitors, such as atezolizumab and pembrolizumab. PD-L1 testing is essential for guiding immunotherapy decisions.

ERBB2 (HER2/neu): Overexpression or amplification of ERBB2 is found in a subset of bladder cancers. HER2-targeted therapies, such as trastuzumab, are being explored for their efficacy in HER2-positive bladder cancer.

Clinical significance

Early detection and diagnosis: Biomarkers play a crucial role in the early detection and diagnosis of bladder cancer. Urinary biomarkers like NMP22, UBC, and survivin offer non-invasive methods to detect bladder cancer, potentially identifying the disease at an earlier stage when it is more treatable [5].

Prognosis and risk stratification: Tissue biomarkers such as FGFR3, TP53, and Ki-67 provide valuable prognostic information. FGFR3 mutations are associated with a better prognosis in NMIBC, while TP53 mutations and high Ki-67 expression are linked to a more aggressive disease course in MIBC. These markers help stratify patients into different risk categories, guiding treatment decisions [6].

Treatment selection and monitoring: Molecular biomarkers like PD-L1 and ERBB2 are essential for selecting appropriate therapies. PD-L1 expression guides the use of immune checkpoint inhibitors, while ERBB2 status can influence the use of HER2-targeted therapies. Additionally, blood biomarkers such as CEA and CA 19-9 are useful for monitoring treatment response and detecting recurrence.

Description

Future prospects

Liquid biopsies: Liquid biopsies involve the analysis of circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and other tumor-derived materials in blood and urine samples. This non-invasive approach offers a promising method for early detection, monitoring of minimal residual disease, and assessing treatment response. Liquid biopsies can detect genetic alterations and mutations, providing insights into tumor dynamics and resistance mechanisms.

Multi-omics approaches: Integrating genomics, proteomics, and metabolomics data can reveal comprehensive biomarker signatures that provide a deeper understanding of bladder cancer biology. Multi-omics approaches can identify novel biomarkers and therapeutic targets, facilitating the development of personalized treatment strategies.

Artificial intelligence and machine learning: AI and ML technologies can analyze large datasets to identify complex biomarker patterns and correlations that traditional analysis methods may miss. These technologies can enhance biomarker discovery, improve diagnostic accuracy, and optimize treatment plans, ultimately leading to better patient outcomes [7].

Tumor microenvironment markers: The tumor microenvironment (TME) plays a crucial role in cancer progression and response to therapy. Biomarkers derived from the TME, including immune cell infiltration profiles and stromal markers, are being investigated to better understand their impact on bladder cancer and identify new therapeutic targets.

Personalized medicine: The integration of biomarker testing into clinical practice enables personalized medicine, tailoring treatment to the individual’s genetic profile and disease characteristics [8]. This approach increases the likelihood of treatment success and minimizes unnecessary side effects, leading to improved patient outcomes.

Conclusion

Biomarkers have become indispensable in the management of bladder cancer, offering new opportunities for early detection, personalized therapy, and improved patient outcomes. Current biomarkers such as NMP22, FGFR3, TP53, PD-L1, and ERBB2 provide valuable insights into disease biology and guide clinical decision-making. Emerging technologies, including liquid biopsies, multi-omics approaches, and AI/ML, hold great promise for advancing biomarker research and enhancing clinical care. Continued research and collaboration are essential to fully realize the potential of biomarkers in bladder cancer, ultimately leading to better clinical outcomes and prolonged survival for patients.

Acknowledgement

None

Conflict of Interest

None

References

1. Timp JF, Braekkan SK,Versteeg HH, Cannegieter SC (2013) Epidemiology of cancer-associated venous thrombosis. Blood 122: 1712-1723.

Indexed at, Google Scholar, Crossref

2. Horsted F, West J, Grainge MJ (2012) Risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysis. PLoS Med 9: 1275.

Indexed at, Google Scholar, Crossref

3. Khorana AA (2010) Venous thromboembolism and prognosis in cancer. Thromb res 125: 490-493.

Indexed at, Google Scholar, Crossref

4. Khorana AA, Dalal MR, Lin J, Connolly GC (2013) Health care costs associated with venous thromboembolism in selected high-risk ambulatory patients with solid tumors undergoing chemotherapy in the United States. Clinicoecon Outcomes Res 5: 101-108.

Indexed at, Google Scholar, Crossref

5. Munoz Martin AJ, Ortega I, Font C, Pachon V, Castellon V, et al. (2018) Multivariable clinical-genetic risk model for predicting venous thromboembolic events in patients with cancer. Br J Cancer 118: 1056-1061.

Indexed at, Google Scholar, Crossref

6. Gerotziafas GT, Taher A, Abdel‐Razeq H, AboElnazar E, Spyropoulos AC, et al. (2017) A predictive score for thrombosis associated with breast, colorectal, lung, or ovarian cancer: the prospective COMPASS-Cancer‐Associated thrombosis study. Oncologist 22: 1222-1231.

Indexed at, Google Scholar, Crossref

7. Ay C, Simanek R, Vormittag R, Dunkler D, Alguel G, et al. (2008) High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). Blood 112: 2703-2708.

Indexed at, Google Scholar, Crossref

8. Mandala M, Barni S, Prins M, Labianca R, Tondini C, et al. (2010) Acquired and inherited risk factors for developing venous thromboembolism in cancer patients receiving adjuvant chemotherapy: a prospective trial. Ann oncol 21: 871-876.

Indexed at, Google Scholar, Crossref